Literature DB >> 16682242

Roles of neuraminidase in the initial stage of influenza virus infection.

Masanobu Ohuchi1, Naoko Asaoka, Tatsuya Sakai, Reiko Ohuchi.   

Abstract

We propose a concept that neuraminidase (NA) promotes virus entry into target cells during the initial stage of viral infection, in addition to the generally accepted concept that influenza virus NA promotes the release of progeny virus from a host cell at the final stage of viral replication. When NA activity was inhibited with specific inhibitors such as zanamivir and oseltamivir carboxylate, infection efficiency of the virus to MDCK and A549 cells was reduced to approximately 1/4 and 1/8, respectively. NA inhibitors did not significantly affect virus binding and envelope fusion activities, when assessed using an erythrocyte and virus system. Since the initial stage of viral infection involves binding of the virus to the target cell, virus entry into an endosome and envelope fusion with the endosomal membrane, our results indicated that NA inhibitors interfered with the virus entry step. Thus, NA is thought to promote virus entry, and thereby enhances infection efficiency.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16682242     DOI: 10.1016/j.micinf.2005.12.008

Source DB:  PubMed          Journal:  Microbes Infect        ISSN: 1286-4579            Impact factor:   2.700


  61 in total

1.  Biological and protective properties of immune sera directed to the influenza virus neuraminidase.

Authors:  Stefan J Halbherr; Thomas H Ludersdorfer; Meret Ricklin; Samira Locher; Marianne Berger Rentsch; Artur Summerfield; Gert Zimmer
Journal:  J Virol       Date:  2014-11-12       Impact factor: 5.103

Review 2.  The Interaction between Respiratory Pathogens and Mucus.

Authors:  Mark Zanin; Pradyumna Baviskar; Robert Webster; Richard Webby
Journal:  Cell Host Microbe       Date:  2016-02-10       Impact factor: 21.023

3.  A mutant influenza virus that uses an N1 neuraminidase as the receptor-binding protein.

Authors:  Kathryn A Hooper; Jesse D Bloom
Journal:  J Virol       Date:  2013-09-11       Impact factor: 5.103

Review 4.  The threat of avian influenza A (H5N1). Part III: Antiviral therapy.

Authors:  Jindrich Cinatl; Martin Michaelis; Hans W Doerr
Journal:  Med Microbiol Immunol       Date:  2007-04-12       Impact factor: 3.402

5.  Transport of influenza virus neuraminidase (NA) to host cell surface is regulated by ARHGAP21 and Cdc42 proteins.

Authors:  Song Wang; Hua Li; Yuhai Chen; Haitao Wei; George F Gao; Hongqiang Liu; Shile Huang; Ji-Long Chen
Journal:  J Biol Chem       Date:  2012-02-08       Impact factor: 5.157

6.  Proximity Ligation-Based Fluorogenic Imaging Agents for Neuraminidases.

Authors:  Zhizeng Gao; Andrew J Thompson; James C Paulson; Stephen G Withers
Journal:  Angew Chem Int Ed Engl       Date:  2018-09-14       Impact factor: 15.336

Review 7.  Single enzyme nanoparticle, an effective tool for enzyme replacement therapy.

Authors:  Dong Hyun Kim; Han Sol Lee; Tae-Wan Kwon; Young-Min Han; Nae-Won Kang; Mee Yeon Lee; Dae-Duk Kim; Myeong Gyu Kim; Jae-Young Lee
Journal:  Arch Pharm Res       Date:  2020-01-27       Impact factor: 4.946

8.  How sticky should a virus be? The impact of virus binding and release on transmission fitness using influenza as an example.

Authors:  Andreas Handel; Victoria Akin; Sergei S Pilyugin; Veronika Zarnitsyna; Rustom Antia
Journal:  J R Soc Interface       Date:  2014-01-15       Impact factor: 4.118

9.  Molecular modeling of swine influenza A/H1N1, Spanish H1N1, and avian H5N1 flu N1 neuraminidases bound to Tamiflu and Relenza.

Authors:  Ly Le; Eric Lee; Klaus Schulten; Thanh N Truong
Journal:  PLoS Curr       Date:  2009-08-27

10.  Enhancement of the influenza A hemagglutinin (HA)-mediated cell-cell fusion and virus entry by the viral neuraminidase (NA).

Authors:  Bin Su; Sébastien Wurtzer; Marie-Anne Rameix-Welti; Dominic Dwyer; Sylvie van der Werf; Nadia Naffakh; François Clavel; Béatrice Labrosse
Journal:  PLoS One       Date:  2009-12-30       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.